Diabetes

Fenugreek seeds extract

Placebo

Evaluation of Fenugreek Seed Extract In Type- 2 Diabetes: An Add-On Study

Clinical Evaluation of Fenugreek Seed Extract In Patients With Type- 2 Diabetes: An Add-On Study

Reduction in fasting blood sugar levels (FBS) (mg/dL)

Reduction in post prandial blood sugar levels (mg/dL)

Chemical Resources

Glucose Intolerance

Postprandial Hyperglycemia

Cardiovascular Risk Factor

Acarbose dose was progressively titrated (50 mg/day per week up to 150 mg/day) to reduce the known adverse effects of acarbose such as flatulence, bloating, diarrhea, abdominal pain.
The treatment for three months

Acarbose

Placebo pills are given instead of acarbose in this group

Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán

Effect of Acarbose on Postprandial Lipoprotein Levels in Glucose Intolerant Patients

In each subject oxLDL is measured using a monoclonal antibody 4E6 based competition (ELISA assay, Mercodia) at 0 and 300 minutes in a postprandial 5 hour test, pre and post-treatment

A 5 hour postprandial test is performed in each patient, were glucose is measured at 0, 5, 10, 20, 30, 60, 120, 180, 240 and 300 minutes, pre and post-treatment

A 5 hour postprandial test is performed in each patient, were insulin is measured at 0, 5, 10, 20, 30, 60, 120, 180, 240 and 300 minutes, pre and post-treatment

We measure basal LDL concentration in each patient, pre and post-treatment

We measure basal HDL concentration in each patient, pre and post-treatment

In each subject ApoB is measured, using nephelometry, at 0 and 300 minutes in a postprandial 5 hour test, pre and post-treatment

acarbose/diarreia

Evaluation of Fenugreek Seed Extract In Type- 2 Diabetes: An Add-On Study

Effect of Acarbose on Postprandial Lipoprotein Levels in Glucose Intolerant Patients

O mais completo banco de dados de ervas medicinais apoiado pela ciência